Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Global Intracellular Targets Made Druggable Market 2018: Industry Analysis of Technologies, Stakeholders, Deals & Trends - TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics

This image opens in the lightbox

News provided by

Research and Markets

01 Feb, 2018, 16:00 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, Feb. 1, 2018 /PRNewswire/ --

The "Intracellular Targets Made Druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: An Industry Analysis of Technologies, Stakeholders, Deals & Trends" report has been added to ResearchAndMarkets.com's offering.

It is estimated that there are 3-4 times more intracellular targets than surface protein targets. However, these intracellular cancer targets are not accessible to traditional monoclonal antibody (mAb) therapies.

Since many of these targets are not enzymes or surface receptors with readily druggable pockets, these important oncogenic proteins cannot be easily inhibited with small molecules. Thus, intracellular cancer-specific proteins, such as mutated oncogene products, transcription factors, protein adapters, and other nontraditional targets, remain inaccessible to current technologies used for FDA-approved drugs.

Therefore, novel technologies are needed to address historically undruggable targets and complex mechanisms, such as intracellular protein-protein interactions like p53 or Ras, -catenin and Myc.

The report furthermore describes the profiles of leading product candidates created by these technologies. The technology companies are presented and analyzed. Deals between Big Pharma and technology companies as well as collaboration and licensing deals between technology companies are highlighted. The value of technologies and product candidates are discussed regarding company acquisition prices, economic deal terms and financing rounds.

Presentation of Target

  • On cell surface as peptide-MHC class I complex
  • Intracellular;
  • Intranuclear
  • Protein-protein interaction (PPI)

Target Examples

  • Neoantigens
  • Gp100; NY-ESO-1; MAGE-A, PRAME; WT1; MART-1
  • Beta-catenin; Myc; Ras

Therapeutic Modality

  • TCR fusion protein
  • TCR-like antibody
  • Cell penetrating peptide, miniprotein or antibody incl. shuttle

Effector Function

  • Fc-enhanced
  • Bispecific (T-cell recruiting)
  • Drug Conjugate
  • Inhibition

This report "Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends" brings you up-to-date regarding key technologies:

  • For identification and validation of intracellular targets,
  • For generation of T-cell receptors (TCR) and TCR fusion proteins,
  • For discovery of TCR-like antibodies, and
  • For construction of cell-penetrating peptides, proteins and antibodies.

What will you find in the report?

Description and comparison of technologies for:

  • Discovery and validation of intracellular targets;
  • Discovery and optimization of T-Cell Receptors (TCRs);
  • Generation of TCR-like or TCR-mimic antibodies;
  • Generation of TCR fusion proteins
  • Generation of cell-penetrating peptides, proteins and antibodies.

Presentation and discussion of profiles of selected product candidates:

  • TCRL antibodies and TCR fusion proteins; and
  • Cell-penetrating peptides, miniproteins and single domain and Ig antibodies

Stakeholder analysis based on profiles of 45 companies active in the field

Key Topics Covered:

1 Executive Summary

2 Introduction & Overview

3 Background

4 Technology Profiles
4.1 Overview & Discussion
4.1.1 Intracellular Target Discovery
4.1.2 TCR Discovery Technologies
4.1.3 Generation of TCR-like Antibodies
4.1.4 Generation of TCR Fusion Proteins against Intracellular Targets
4.1.5 Generation of Cell Penetrating Biologics against Intracellular Targets
4.2 Technologies for Discovery of Intracellular Targets
4.2.1 XPRESIDENT
4.2.2 Targets for TCRs (Immunocore)
4.2.3 Phosphopeptide Library
4.2.4 HTS Platform for Neoantigen Identification
4.2.5 ECLIPSE Platform
4.2.6 EpiTarget Platform
4.2.7 Soluble HLA (sHLA) Molecules
4.2.8 Phagemers & SSIp display
4.2.9 Peptide/MHC Complexes
4.2.10 TCR Target Discovery
4.3 Technologies for Discovery of TCRs
4.3.1 Naturally Selected TCRs
4.3.2 TCRs by ImmTAC Technology
4.3.3 HTS for TUMAP-Restricted TCRs
4.3.4 Natural TCR Library
4.3.5 Sleeping-Beauty Expression System
4.3.6 TCR-GENerator
4.3.7 T-Rx Mammalian TCR Display
4.3.8 Single Cell Sequencing Platform
4.3.9 Immune Repertoire Capture
4.3.10 Combinatorial TCR Exchange (CTE)
4.3.11 VelociT for T-Cell Receptor Discovery
4.4 Technologies for Generation of TCRL Antibodies
4.4.1 TandAb
4.4.2 BiTE
4.4.3 E-Alpha Phage Display
4.4.4 HuTARG Protein Engineering
4.4.5 MAR & TriTE
4.4.6 TCRL Antibodies
4.4.7 TCRm Antibodies
4.4.8 Ylanthia Fab library
4.4.9 TCRL ADCs
4.5 Technologies for Generation of TCR Fusion Proteins
4.5.1 ImmTAC
4.5.2 TCR Bispecifics
4.5.3 STAR
4.6 Technologies for Generation of Cell Penetrating Biologics
4.6.1 Cell-Penetrating alpha Bodies
4.6.2 Anti-DNA Autoantibodies
4.6.3 Cell Penetrating Mini Proteins (CPMP)
4.6.4 Feldan Shuttle
4.6.5 Shark VNARs
4.6.6 iMab
4.6.7 iTABs
4.6.8 Stapled Peptides
4.6.9 Single Domain Antibodies

5 Pipeline Analysis and Product Profiles
5.1 Overview Product Profiles and Pipeline Discussion
5.2 Profiles of Selected TCRL Antibodies & TCR Fusion Proteins
5.2.1 IMCgp100
5.2.2 ALT-801
5.2.3 H8F4
5.2.4 MMP1-003 TandAb
5.2.5 ESK1 & ESKM
5.2.6 RL1B
5.3 Profiles of Selected Cell Penetrating Peptides, Proteins & Antibodies
5.3.1 ALRN-6924
5.3.2 Anti-Mcl-1 CPAB
5.3.3 PAT-DX1 & Other Deoxymabs
5.3.4 RT11-i
5.3.5 SBT-100

6 Stakeholder Analysis & Company Profiles
6.1 Stakeholder Analysis and Overview of Company Profiles
6.2 Profiles of Companies with Target Discovery and TCR Fusion Protein Technologies
6.2.1 Agenus
6.2.2 Atreca
6.2.3 Immatics Biotechnologies
6.2.4 Immunocore
6.2.5 Regeneron Pharmaceuticals
6.3 Profiles of Companies with Target Discovery and TCR-Like Antibody Technologies
6.3.1 AbeXXa
6.3.2 Adicet Bio
6.3.3 MD Anderson Cancer Center
6.3.4 Pure MHC
6.4 Profiles of Companies with TCR Fusion Protein and/or TCRL Antibody Technologies
6.4.1 Affimed Therapeutics
6.4.2 NantCell (Altor Bioscience)
6.4.3 Eureka Therapeutics
6.4.4 Innovative Targeting Solutions (ITS)
6.4.5 Morphosys
6.4.6 Receptor Logic (now Pure MHC)
6.4.7 Timmune Biotech
6.5 Profiles of Companies with TCR Discovery Technologies only used for T-Cell Therapy
6.5.1 BioNTech
6.5.2 Gadeta
6.5.3 Gilead Sciences (Kite Pharma)
6.5.4 Juno Therapeutics
6.5.5 Medigene
6.5.6 ZIOPHARM Oncology
6.6 Profiles of Companies with Cell Penetrating (CP) Peptide, Protein or Antibody Technologies
6.6.1 Aileron Therapeutics
6.6.2 Complix
6.6.3 Elasmogen
6.6.4 Feldan Therapeutics
6.6.5 Fog Pharmaceuticals
6.6.6 Orum Pharmaceuticals
6.6.7 Patrys
6.6.8 Singh Biotechnology
6.6.9 Sorrento Therapeutics & LA Cell
6.7 Profiles of Big Pharma & Biotech Companies Active in the Intracellular Target and TCR & Cell Penetrating Biologics Field
6.7.1 AbbVie
6.7.2 Amgen
6.7.3 Astellas Pharma
6.7.4 AstraZeneca
6.7.5 Boehringer Ingelheim
6.7.6 Eli Lilly
6.7.7 GlaxoSmith-Kline
6.7.8 Janssen Biotech
6.7.9 Merck
6.7.10 Novartis
6.7.11 Roche
6.8 Profiles of Other Companies with Stakes in the Field of Intracellular Targets and TCR & Cell Penetrating Biologics
6.8.1 Nextera
6.8.2 Xencor
6.8.3 Zymeworks

7 Deals & Financing
7.1 Partnering Deals between Big Pharma and Technology Companies
7.2 Acquisitions of Technology Companies
7.3 Collaboration and Licensing Deals between Technology Companies
7.4 Financing Sources of Technology Companies

8 Trends & Outlook

9 References

For more information about this report visit https://www.researchandmarkets.com/research/43tgc2/global?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.